Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Return on Capital (ROC)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Return on Invested Capital (ROIC)

Merck & Co. Inc., ROIC calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Invested capital2
Performance Ratio
ROIC3
Benchmarks
ROIC, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 NOPAT. See details »

2 Invested capital. See details »

3 2025 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The period under review demonstrates significant fluctuations in Return on Invested Capital (ROIC). Net operating profit after taxes (NOPAT) and invested capital both experienced growth initially, followed by a substantial disruption, and then a recovery. These movements directly impacted the ROIC performance.

Net Operating Profit After Taxes (NOPAT)
NOPAT increased from US$13,349 million in 2021 to US$14,154 million in 2022, indicating improved operational profitability. However, a dramatic decline occurred in 2023, with NOPAT falling to a loss of US$714 million. A strong recovery followed in 2024, reaching US$16,744 million, and continued growth into 2025, reaching US$17,864 million. This suggests a period of significant challenge in 2023, followed by a successful turnaround.
Invested Capital
Invested capital generally trended upward throughout the period. It rose from US$70,735 million in 2021 to US$73,942 million in 2022. A slight decrease was observed in 2023, falling to US$69,966 million, potentially reflecting asset divestitures or reduced investment. Subsequent increases were noted in 2024 (US$79,426 million) and 2025 (US$97,963 million), indicating a renewed commitment to capital deployment.
Return on Invested Capital (ROIC)
The ROIC mirrored the volatility in NOPAT. It began at a robust 18.87% in 2021 and increased slightly to 19.14% in 2022. The substantial decline in NOPAT in 2023 resulted in a negative ROIC of -1.02%. A significant rebound occurred in 2024, with ROIC reaching 21.08%, the highest value in the observed period. While remaining positive, ROIC decreased to 18.24% in 2025, suggesting a moderation from the peak performance achieved in the prior year. The large swings in ROIC highlight the sensitivity of this metric to changes in NOPAT.

The substantial negative ROIC in 2023 warrants further investigation to understand the underlying causes of the NOPAT decline. The subsequent recovery in both NOPAT and ROIC demonstrates a successful response to those challenges. The continued growth in invested capital, particularly in 2025, suggests ongoing strategic initiatives requiring capital allocation.


Decomposition of ROIC

Merck & Co. Inc., decomposition of ROIC

Microsoft Excel
ROIC = OPM1 × TO2 × 1 – CTR3
Dec 31, 2025 = × ×
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Operating profit margin (OPM). See calculations »

2 Turnover of capital (TO). See calculations »

3 Effective cash tax rate (CTR). See calculations »


The period under review demonstrates significant fluctuations in the components of return on invested capital. Operating profit margin, turnover of capital, and the impact of the effective cash tax rate all exhibit distinct trends that contribute to the observed changes in ROIC.

Operating Profit Margin (OPM)
The operating profit margin initially remained relatively stable between 2021 and 2022, at approximately 30%. A substantial decline was then observed in 2023, falling to 4.63%. However, the OPM experienced a strong recovery in subsequent years, reaching 32.71% in 2024 and further increasing to 34.55% in 2025. This suggests potential shifts in cost management, pricing strategies, or product mix over the period.
Turnover of Capital (TO)
The turnover of capital showed an increasing trend from 2021 to 2023, rising from 0.69 to 0.86. This indicates improving efficiency in utilizing capital to generate revenue. However, the trend reversed in 2024, with a decrease to 0.81, followed by a more pronounced decline to 0.66 in 2025. This suggests a potential slowdown in revenue generation relative to the capital employed in the later years.
Effective Cash Tax Rate (1 – CTR)
The metric (1 – Effective cash tax rate) was relatively high and stable between 2021 and 2022, at approximately 89.6% and 79.0% respectively. A significant and negative value was recorded in 2023 (-25.66%), indicating a substantial tax benefit or a change in tax liabilities. The value then returned to a level similar to 2022 in 2024 and 2025, stabilizing around 79.8% and 79.5% respectively. This volatility significantly impacts the after-tax profitability reflected in ROIC.
Return on Invested Capital (ROIC)
The ROIC generally tracked the combined effects of the aforementioned factors. It remained relatively stable around 18.9% in 2021 and 2022. The negative effective cash tax rate in 2023 resulted in a negative ROIC of -1.02%. The strong recovery in operating profit margin in 2024 drove a substantial increase in ROIC to 21.08%. However, the decline in turnover of capital in 2025 contributed to a decrease in ROIC to 18.24%, despite the continued high operating profit margin. The interplay between profitability, efficiency, and tax effects is clearly demonstrated in the ROIC trend.

In summary, the period was characterized by dynamic shifts in profitability, capital utilization, and tax implications, resulting in a fluctuating ROIC. The substantial decline in operating profit margin in 2023, coupled with the unusual tax benefit, had a significant impact on overall returns. While profitability recovered strongly in 2024, a subsequent decline in capital turnover tempered ROIC gains in 2025.


Operating Profit Margin (OPM)

Merck & Co. Inc., OPM calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Add: Cash operating taxes2
Net operating profit before taxes (NOPBT)
 
Sales
Profitability Ratio
OPM3
Benchmarks
OPM, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2025 Calculation
OPM = 100 × NOPBT ÷ Sales
= 100 × ÷ =

4 Click competitor name to see calculations.


The operating profit margin exhibited considerable fluctuation over the five-year period. Initial values were strong, followed by a significant decline, and then a robust recovery and continued growth.

Operating Profit Margin (OPM)
In 2021 and 2022, the OPM remained relatively stable, registering at 30.60% and 30.22% respectively. This indicates a consistent level of profitability from core operations during these years.
A substantial decrease in OPM was observed in 2023, falling to 4.63%. This represents a significant erosion of profitability and warrants further investigation into the underlying causes, potentially related to increased costs or decreased sales efficiency.
The OPM demonstrated a strong recovery in 2024, increasing to 32.71%. This suggests successful implementation of cost control measures, improved pricing strategies, or a favorable shift in the sales mix.
The upward trend continued into 2025, with the OPM reaching 34.55%. This represents the highest level of profitability within the observed period, indicating enhanced operational efficiency and potentially stronger market positioning.

Net operating profit before taxes mirrored the OPM trend, with a decline in 2023 and subsequent recovery. Sales showed consistent growth throughout the period, although the largest increase occurred between 2021 and 2022. The combination of sales growth and improving OPM in the later years contributed to substantial increases in net operating profit before taxes.

The volatility in the OPM highlights the importance of ongoing monitoring and analysis of cost structures and revenue drivers. The recent positive trend suggests successful strategic adjustments, but continued vigilance is necessary to sustain these improvements.


Turnover of Capital (TO)

Merck & Co. Inc., TO calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Sales
Invested capital1
Efficiency Ratio
TO2
Benchmarks
TO, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Invested capital. See details »

2 2025 Calculation
TO = Sales ÷ Invested capital
= ÷ =

3 Click competitor name to see calculations.


The turnover of capital exhibited fluctuating performance over the five-year period. Initial increases were followed by a decline, suggesting shifts in the efficiency with which invested capital generated sales.

Overall Trend
The turnover of capital generally increased from 2021 to 2023, peaking at 0.86 in 2023, before decreasing in the subsequent two years. This indicates an initial improvement in capital utilization followed by a weakening trend.
Sales Performance
Sales demonstrated consistent growth from 2021 to 2025, increasing from US$48,704 million to US$65,011 million. This positive sales trajectory did not consistently translate into improved capital turnover.
Invested Capital
Invested capital initially increased from US$70,735 million in 2021 to US$73,942 million in 2022, then decreased to US$69,966 million in 2023. A substantial increase was observed in 2024, reaching US$79,426 million, and continued to rise significantly to US$97,963 million in 2025. The increasing invested capital in later years, coupled with a declining turnover ratio, suggests diminishing returns on capital.
Turnover of Capital – Detailed Analysis
The turnover of capital rose from 0.69 in 2021 to 0.80 in 2022, and further to 0.86 in 2023, indicating improved efficiency in generating sales from each dollar of invested capital. However, this positive trend reversed in 2024, with the ratio decreasing to 0.81. The most significant decline occurred in 2025, with the turnover of capital falling to 0.66. This final decrease suggests a substantial reduction in the efficiency of capital utilization despite continued sales growth.

The divergence between sales growth and the turnover of capital in 2024 and 2025 warrants further investigation. The substantial increase in invested capital during these years, without a corresponding increase in capital turnover, may indicate inefficient capital allocation or investments that have not yet yielded sufficient returns.


Effective Cash Tax Rate (CTR)

Merck & Co. Inc., CTR calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Add: Cash operating taxes2
Net operating profit before taxes (NOPBT)
Tax Rate
CTR3
Benchmarks
CTR, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2025 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =

4 Click competitor name to see calculations.


The effective cash tax rate exhibited considerable fluctuation over the five-year period. Cash operating taxes generally increased, though not consistently, while net operating profit before taxes demonstrated a more volatile pattern. These movements significantly impacted the calculated effective cash tax rate.

Effective Cash Tax Rate (CTR)
In 2021, the effective cash tax rate was 10.42%. This increased substantially to 20.99% in 2022, indicating a higher proportion of pre-tax profits being paid in cash taxes. A dramatic spike occurred in 2023, with the rate reaching 125.66%. This suggests a significantly disproportionate amount of cash taxes paid relative to pre-tax income, potentially due to one-time events or changes in tax regulations. The rate then decreased to 20.23% in 2024 and remained relatively stable at 20.47% in 2025. The 2023 outlier warrants further investigation to understand the underlying cause.

Net operating profit before taxes increased from US$14,902 million in 2021 to US$17,914 million in 2022. However, it experienced a substantial decline to US$2,783 million in 2023, before recovering to US$20,990 million in 2024 and further increasing to US$22,461 million in 2025. This volatility in NOPBT directly influences the interpretation of the CTR, particularly in 2023.

Cash operating taxes showed an increasing trend overall, rising from US$1,553 million in 2021 to US$4,597 million in 2025. However, the growth was not linear, with a significant increase from 2021 to 2022, a slight decrease from 2022 to 2023, and then further increases in 2024 and 2025. The relationship between cash taxes and NOPBT is not consistent across all periods, contributing to the fluctuations in the effective cash tax rate.

The substantial increase in the effective cash tax rate in 2023, coupled with the simultaneous decrease in net operating profit before taxes, suggests a potentially significant impact from specific tax-related items or a change in the company’s tax position during that year. Further analysis of the components of cash operating taxes and NOPBT for 2023 is recommended to fully understand this anomaly.